LOADINGLoading your Pro surface...
The Avelor narrative
Direction: a light gate. Enter your email and the access code from your invite to view the pitch.
Avelor is the intelligence layer for everything you take.
Direction: the only platform that recognizes and safety-checks your whole stack, every supplement and every clinic-prescribed Rx, peptide, and hormone, grounded in primary literature. It works with your labs and your clinic, not against either.
Almost everyone takes something, and no one owns whole-stack safety and intelligence.
A multi-trillion-dollar surface, entered through the sharpest wedge.
Market sizing: CMS, KFF, Grand View Research, Fortune Business Insights, GWI, 2024-2026. Pricing, ARPU, TAM, SAM, SOM, ARR, and enterprise-value figures are Avelor internal estimates and forward projections, not guarantees.
The category we are building: the AI operating system for personal health.
Not supplements. Not labs. Not another wellness app. A recurring, science-grounded intelligence layer across everything you take and everything your body shows, for consumers and for the clinics that serve them.
Year-5 ARR is under 3% of the $7.0B category. The ceiling is the category; today we own the wedge.
The ramp comes from three engines: the consumer subscription, the B2B white-label layer, and partner-prescriber revenue, with owned care last, only if the economics become undeniable.
Two engines, one compounding platform.
Two revenue engines on one platform: a tiered consumer subscription, and the same engine white-labeled into the clinics already managing the most complex stacks - longevity, hormone, GLP-1 telehealth, functional medicine, and concierge.
For scale reference, one provider-software footprint (Press Ganey Forsta) already reaches 41,000 healthcare organizations.
Avelor stays the intelligence layer. Treatment intent routes to partner prescribers and clinics, so Avelor keeps software margins and a software multiple. We add owned care last, only if the economics become undeniable.
An intelligent health copilot, in one platform of four surfaces.
Direction: Home (Avelor Protocol), Ask Avelor (the advisor + Crosscheck), Progress (Avelor Signal), Profile (Avelor Lens). Confirm-first agentic action, long-term memory, PubMed-grounded protocols, messaging-native.
A compounding data moat: 35,996 studies screened to 7,651 PubMed-grade citations, 423 published supplement-drug interactions, and a whole-stack knowledge graph.
Served live from the database. Refreshes nightly as the moat compounds.
Built fast, with an audience already waiting.
What we are building next.
The next 18 months turn the wedge into a proven, repeatable platform. This is the proof we are executing against.
The near-term goal: a base of paid subscribers, an efficient and repeatable acquisition engine, the first clinic pilots, and a compounding evidence moat.
Five revenue lines, one compounding platform.
Direction: the consumer to clinician to prescribing arc. Intelligence now; prescribing belongs to a separate licensed medical entity later.
A founder with an audience, an advisory board, and a build engine.
Direction: Ben plus the Avelor Research and Clinical Advisory Board (named clinicians gated on consent) plus the multi-agent build engine as its own story.
Intelligence now. Prescribing later. The health OS.
The round, use of funds, and milestones live in the data room.
Direction: round size, use of funds, and milestones are NOT on this page. They live in a real, access-controlled data room.
Open the data room